MX2023004704A - Nanoestructuras proteicas auto-ensamblables que muestran proteinas f de paramixovirus y/o neumovirus y su uso. - Google Patents

Nanoestructuras proteicas auto-ensamblables que muestran proteinas f de paramixovirus y/o neumovirus y su uso.

Info

Publication number
MX2023004704A
MX2023004704A MX2023004704A MX2023004704A MX2023004704A MX 2023004704 A MX2023004704 A MX 2023004704A MX 2023004704 A MX2023004704 A MX 2023004704A MX 2023004704 A MX2023004704 A MX 2023004704A MX 2023004704 A MX2023004704 A MX 2023004704A
Authority
MX
Mexico
Prior art keywords
pneumovirus
paramyxovirus
proteins
self
assemblies
Prior art date
Application number
MX2023004704A
Other languages
English (en)
Inventor
Antonio Lanzavecchia
David Baker
Neil P King
Brooke Nickerson
Lance Joseph Stewart
Laurent Perez
Jessica Marcandalli
Original Assignee
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Washington filed Critical Univ Washington
Publication of MX2023004704A publication Critical patent/MX2023004704A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
    • C12N2760/18322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
    • C12N2760/18334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nanotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Medical Informatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

El presente documento describe nanoestructuras y su uso, en donde las nanoestructuras incluyen (a) una pluralidad de primeros ensamblajes, cada primer ensamblaje comprende una pluralidad de primeros polipéptidos idénticos; (b) una pluralidad de segundos ensamblajes, cada segundo ensamblaje comprende una pluralidad de segundos polipéptidos idénticos, en donde el segundo polipéptido difiere del primer polipéptido; en donde la pluralidad de primeros ensamblajes interactúa de manera no covalente con la pluralidad de segundos ensamblajes para formar una nanoestructura; y en donde la nanoestructura muestra múltiples copias de una o más proteínas F de paramixovirus y/o neumovirus o fragmentos antigénicos de las mismas, en un exterior de la nanoestructura.
MX2023004704A 2017-04-04 2019-10-02 Nanoestructuras proteicas auto-ensamblables que muestran proteinas f de paramixovirus y/o neumovirus y su uso. MX2023004704A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762481331P 2017-04-04 2017-04-04

Publications (1)

Publication Number Publication Date
MX2023004704A true MX2023004704A (es) 2023-05-09

Family

ID=62116943

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019011869A MX2019011869A (es) 2017-04-04 2018-04-03 Nanoestructuras proteicas auto-ensamblables que muestran proteinas f de paramixovirus y/o neumovirus y su uso.
MX2023004704A MX2023004704A (es) 2017-04-04 2019-10-02 Nanoestructuras proteicas auto-ensamblables que muestran proteinas f de paramixovirus y/o neumovirus y su uso.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2019011869A MX2019011869A (es) 2017-04-04 2018-04-03 Nanoestructuras proteicas auto-ensamblables que muestran proteinas f de paramixovirus y/o neumovirus y su uso.

Country Status (14)

Country Link
US (3) US11192926B2 (es)
EP (1) EP3606942A1 (es)
JP (2) JP7168938B2 (es)
KR (1) KR20190140916A (es)
CN (3) CN115779077A (es)
AU (2) AU2018249533C1 (es)
BR (1) BR112019020661A2 (es)
CA (1) CA3058794A1 (es)
IL (1) IL269643A (es)
MX (2) MX2019011869A (es)
PH (1) PH12019502276A1 (es)
RU (1) RU2019130167A (es)
SG (1) SG11201908999QA (es)
WO (1) WO2018187325A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9630994B2 (en) * 2014-11-03 2017-04-25 University Of Washington Polypeptides for use in self-assembling protein nanostructures
AU2019228551A1 (en) 2018-02-28 2020-10-15 University Of Washington Self-assembling nanostructure vaccines
EP3921332A2 (en) 2019-02-08 2021-12-15 The USA, as represented by The Secretary, Department of Health and Human Services Nanoparticle-based influenza virus vaccines and uses thereof
EP4025587A1 (en) * 2019-09-04 2022-07-13 University of Washington Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus f proteins and their use
CN110878128A (zh) * 2019-11-04 2020-03-13 中国疾病预防控制中心病毒病预防控制所 一种人呼吸道合胞病毒粘膜疫苗及其制备方法和应用
AU2021220958A1 (en) * 2020-02-14 2022-09-01 University Of Washington Polypeptides and their use
US20230227790A1 (en) * 2020-06-09 2023-07-20 Scot R. Shepard Method of assemblying two-component virus-like particle
WO2021252687A2 (en) * 2020-06-09 2021-12-16 Icosavax, Inc. Method of making virus-like particle
CN111991556B (zh) * 2020-10-29 2021-03-02 中山大学 SARS-CoV-2 RBD共轭纳米颗粒疫苗
CN117202928A (zh) 2020-11-13 2023-12-08 Icosavax股份有限公司 用于偏肺病毒的基于蛋白质的纳米颗粒疫苗
CN112778404B (zh) * 2021-01-28 2022-11-29 中山大学 一种含EB病毒gHgL蛋白的自组装纳米颗粒及其制备方法与应用
WO2023225562A1 (en) 2022-05-17 2023-11-23 Icosavax, Inc. Multivalent vaccine for paramyxoviruses and uses thereof

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4238904A1 (de) 1992-11-19 1994-05-26 Basf Ag Riboflavin-Synthese in Hefen
JP2000152791A (ja) 1998-11-11 2000-06-06 E I Du Pont De Nemours & Co ルマジンシンターゼおよびリボフラビンシンターゼ
AU2005287383B2 (en) 2004-05-25 2011-09-22 Chimeros, Inc. Self-assembling nanoparticle drug delivery system
EP3073267A1 (en) 2004-09-21 2016-09-28 Medimmune, Inc. Antibodies against and methods for producing vaccines for respiratory syncytial virus
EP4219566A3 (en) 2007-12-24 2023-09-06 ID Biomedical Corporation of Quebec Recombinant rsv antigens
WO2010019725A2 (en) 2008-08-12 2010-02-18 Salemme Francis R Node polypeptides for nanostructure assembly
GB0817507D0 (en) 2008-09-24 2008-10-29 Ucl Business Plc Protein cages
ES2582005T3 (es) 2008-12-09 2016-09-08 Novavax, Inc. Proteínas F del RSV modificadas y métodos de su uso
US20110200560A1 (en) 2009-05-26 2011-08-18 Massachusetts Institute Of Technology Non-ionic self-assembling peptides and uses thereof
WO2011017835A1 (en) 2009-08-11 2011-02-17 Nanjing University Preparation method of protein or peptide nanoparticles for in vivo drug delivery by unfolding and refolding
BR112013000345B1 (pt) 2010-07-07 2021-11-23 Artificial Cell Technologies, Inc Composição compreendendo partículas contendo epítopos de rsv
SG194755A1 (en) 2011-05-13 2013-12-30 Novartis Ag Pre-fusion rsv f antigens
EP2758038B1 (en) 2011-09-23 2018-05-30 The United States of America, as represented by The Secretary, Department of Health & Human Services Novel influenza hemagglutinin protein-based vaccines
CN104080476A (zh) 2011-09-30 2014-10-01 诺瓦瓦克斯股份有限公司 用于呼吸道合胞病毒的重组纳米颗粒rsv f疫苗
EP2766030A4 (en) 2011-10-12 2015-09-16 Univ Washington GP120 GENETICALLY MODIFIED EXTERNAL DOMAIN (EOD) OF HIV AND ASSOCIATED MUTANTS
JP2015514132A (ja) 2012-04-10 2015-05-18 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア ヒト呼吸器合胞体ウイルスコンセンサス抗原、核酸構築物、およびそれらから作製されるワクチン、ならびにその使用方法
US8969521B2 (en) 2012-04-11 2015-03-03 University Of Washington Through Its Center For Commercialization General method for designing self-assembling protein nanomaterials
WO2014005643A1 (en) 2012-07-05 2014-01-09 Okairos Ag Novel prime-boosting regimens involving immunogenic polypeptides encoded by polynucleotides
MX362511B (es) 2012-08-01 2019-01-22 Bavarian Nordic As Vacuna del virus vaccinia ankara modificado (mva) recombinante para virus sincicial respiratorio (vsr).
KR20150085843A (ko) 2012-11-20 2015-07-24 글락소스미스클라인 바이오로지칼즈 에스.에이. Rsv f 융합전 삼합체
US20140141037A1 (en) 2012-11-20 2014-05-22 Novartis Ag Rsv f prefusion trimers
WO2014124301A1 (en) 2013-02-07 2014-08-14 University Of Washington Through Its Center For Commercialization Self-assembling protein nanostructures
US9738689B2 (en) 2013-03-13 2017-08-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion RSV F proteins and their use
AU2014243756B2 (en) 2013-03-13 2018-09-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion RSV F proteins and their use
US9060975B2 (en) 2013-03-14 2015-06-23 Mucosis Bv Heat-stable respiratory syncytial virus F protein oligomers and their use in immunological compositions
EP2975052B1 (en) 2013-03-15 2020-09-23 Xiamen University Epitope of rsv fusion protein and antibody identifying same
EP2988780B1 (en) 2013-04-25 2018-12-26 Janssen Vaccines & Prevention B.V. Stabilized soluble prefusion rsv f polypeptides
CN105408348B (zh) 2013-06-17 2021-07-06 扬森疫苗与预防公司 稳定化的可溶性融合前rsv f多肽
CA2925201A1 (en) 2013-09-24 2015-04-02 Massachusetts Institute Of Technology Self-assembled nanoparticle vaccines
US20150166610A1 (en) 2013-10-14 2015-06-18 Glaxosmithkline Biologicals, S.A. Recombinant rsv antigens
EP2974739A1 (en) 2014-07-15 2016-01-20 Novartis AG RSVF trimerization domains
US9630994B2 (en) 2014-11-03 2017-04-25 University Of Washington Polypeptides for use in self-assembling protein nanostructures
SG11201705264WA (en) 2014-12-31 2017-07-28 The Usa As Represented By The Secretary Detp Of Health And Human Services Novel multivalent nanoparticle-based vaccines
US10501733B2 (en) 2015-02-27 2019-12-10 University Of Washington Polypeptide assemblies and methods for the production thereof
WO2016160166A1 (en) 2015-03-30 2016-10-06 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Immunogenic rsv polypeptides
PL3319633T3 (pl) 2015-07-07 2021-04-19 Janssen Vaccines & Prevention B.V. Szczepionka przeciwko rsv
KR20180026734A (ko) 2015-07-07 2018-03-13 얀센 백신스 앤드 프리벤션 비.브이. 안정화된 가용성 융합-전 rsv f 폴리펩티드
WO2017027480A1 (en) 2015-08-13 2017-02-16 Echogen Power Systems, L.L.C. Heat engine system including an integrated cooling circuit
US11324816B2 (en) 2015-08-31 2022-05-10 Technovax, Inc. Human respiratory syncytial virus (HRSV) virus-like particles (VLPS) based vaccine
IL257800B2 (en) 2015-09-03 2023-11-01 Novavax Inc Immune compositions with improved stability and immunogenicity
MX2018005462A (es) 2015-10-29 2018-08-01 Univ Emory Composiciones inmunogénicas de rsv quimérico y métodos de uso.
KR102136678B1 (ko) 2015-12-23 2020-07-22 화이자 인코포레이티드 Rsv f 단백질 돌연변이체
AU2017242020B2 (en) 2016-03-29 2021-08-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Substitutions-modified prefusion RSV F proteins and their use
WO2017174568A1 (en) 2016-04-05 2017-10-12 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion rsv f proteins
DK3464331T3 (da) 2016-05-30 2021-01-18 Janssen Vaccines & Prevention Bv Stabiliserede præfusions-rsv f-proteiner
WO2017207477A1 (en) 2016-05-30 2017-12-07 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv f proteins
US10961283B2 (en) 2016-06-27 2021-03-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Self-assembling insect ferritin nanoparticles for display of co-assembled trimeric antigens
EP3554538A2 (en) 2016-12-16 2019-10-23 Institute for Research in Biomedicine Novel recombinant prefusion rsv f proteins and uses thereof

Also Published As

Publication number Publication date
US11732011B2 (en) 2023-08-22
IL269643A (en) 2019-11-28
US11192926B2 (en) 2021-12-07
MX2019011869A (es) 2020-01-09
US20200392187A1 (en) 2020-12-17
JP2023002680A (ja) 2023-01-10
CN115947873A (zh) 2023-04-11
PH12019502276A1 (en) 2020-09-28
EP3606942A1 (en) 2020-02-12
AU2018249533B2 (en) 2022-01-27
AU2018249533C1 (en) 2023-10-12
US20220169681A1 (en) 2022-06-02
RU2019130167A3 (es) 2021-12-22
WO2018187325A1 (en) 2018-10-11
CN115779077A (zh) 2023-03-14
JP7168938B2 (ja) 2022-11-10
AU2018249533A1 (en) 2019-10-17
SG11201908999QA (en) 2019-10-30
CA3058794A1 (en) 2018-10-11
KR20190140916A (ko) 2019-12-20
AU2022202787A1 (en) 2022-05-19
BR112019020661A2 (pt) 2020-05-05
JP2020515280A (ja) 2020-05-28
CN110603262A (zh) 2019-12-20
RU2019130167A (ru) 2021-05-05
US20240150411A1 (en) 2024-05-09

Similar Documents

Publication Publication Date Title
PH12019502276A1 (en) Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus f proteins and their use
CL2022003378A1 (es) Péptidos y combinaciones para uso en inmunoterapia contra el cáncer de páncreas y otros cánceres (solicitud divisional 201703235)
WO2016073906A3 (en) Transforming growth factor-related immunoassays
JP2014132019A5 (es)
MX2017009538A (es) Antigenos de citomegalovirus y su uso.
WO2019068018A3 (en) Recombinant collagen and elastin molecules and uses thereof
WO2015187809A3 (en) Techniques to isolating a portion of an online computing service
CY1124727T1 (el) Πρωτεϊνες συντηξης tatk-cdkl5, συνθεσεις, φαρμακοτεχνικες μορφες και η χρηση αυτων
EP3833683A4 (en) POLYPEPTIDE INTEGRIN ANTAGONISTS
ES2722773T3 (es) Polipéptidos de fHbp meningocócicos modificados
EP4300464A3 (en) Displaying performance limitations in aircraft display
EP3360895A3 (en) Preparation comprising factor viii and von willebrand factor peptides
EP3737399A4 (en) ATF5 PEPTIDIC VARIANTS AND THEIR USES
EP3912989A4 (en) PENETRATING PEPTIDE BASED ON THE M2 PROTEIN OF THE INFLUENZA VIRUS
EP3906057A4 (en) ANTI-TCR ANTIBODY MOLECULES AND THEIR USES
CL2020000862A1 (es) Composición de proteína de guisante con calidad nutricional mejorada.
WO2020068196A3 (en) Proteins that inhibit cas12a (cpf1), a crispr-cas nuclease
EP3740228A4 (en) PEPTIDES AND THEIR USES
EP3666897A4 (en) VERY VERSATILE PROCESS FOR REPRESENTING A CYCLIC PEPTID ON A PROTEIN STRUCTURE
EP4058483A4 (en) ANTI-TCR ANTIBODY MOLECULES AND THEIR USES
EP3617317A4 (en) PEPTIDIC SUPPORT FOR THE DISPLAY OF A TARGET POLYPEPTIDE AND ASSOCIATED USE
EP3634145A4 (en) POLYPEPTIDE, USE AND PROCESS FOR HYDROLYSIS OF PROTEIN
WO2018174668A3 (ko) 인슐린 수용체와의 결합력이 감소된 인슐린 아날로그의 결합체 및 이의 용도
EP3959225A4 (en) CD80 VARIANT PROTEINS AND THEIR USES
EP3687578A4 (en) HYDROGELS OF POLYIONIC POLYPEPTIDE COMPLEXES AND THEIR USES